Dr. Vogel to Lead Joint Breast Cancer Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly established joint breast cancer program of the University of Pittsburgh Cancer Institute and Magee-Womens Hospital. He will also join the University of Pittsburgh as professor of medicine and epidemiology.

PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly establishedjoint breast cancer program of the University of Pittsburgh CancerInstitute and Magee-Womens Hospital. He will also join the Universityof Pittsburgh as professor of medicine and epidemiology.

Dr. Vogel comes to Pittsburgh from the University of Texas M.D.Anderson Cancer Center, where he was responsible for recruitingthe largest number of women onto the Breast Cancer PreventionTrial, the national study designed to determine the value of tamoxifen(Nolva-dex) in preventing breast cancer in high-risk women.

"One of the program's most important missions," Dr.Vogel said, "will be to enhance delivery of care to womenwho face barriers, ie, older women or those who are poor or livein rural areas."

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content